GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs

By Bhanvi Satija and Raechel Thankam Job LONDON, July 28 (Reuters) – GSK launched a £1.9 billion ($2.52 billion) cost-savings effort on Tuesday to help fund the British drugmaker's expanded late-stage

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)